Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Discovery May Revolutionize Therapy In Muscular Dystrophy And Other Skeletal Muscle Disorders
Researchers at UMDNJ-Robert Wood Johnson Medical School are a step closer to treating, and perhaps preventing, muscle damage caused by disease and aging. In their study, published in the June issue of Journal of Biological Chemistry, the scientists have linked the newly discovered protein MG53 to a pathway that repairs human muscle tissue along with the proteins caveolin-3 (Cav3) and dysferlin. Prior to this study, the underlying interactions that inhibited membrane repair in muscle tissue were unknown. Linking these proteins creates a mechanism that allows damaged membranes to be repaired, which may transform treatment for patients who suffer from severe complications of diseases such as muscular dystrophy, as well as cardiovascular disorders and conditions related to advancing age.
buy viagra
Care Quality Commission Sets Out The Parameters Of Its Review Of Take Care Now's Out-of-hours GP Services
The Care Quality Commission (CQC) today outlines the scope of its review of the provision and commissioning of out-of-hours GP services run by Take Care Now.
plan for health
News of the day
Risks Of Delaying Anterior Cruciate Ligament Reconstruction In Young Athletes May Be Too High, Study Shows
More and more children are participating and getting hurt playing sports each year. A
Endocrinology

PolyMedix Receives United States Patent For Angiogenesis Inhibitor Compounds

PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, announced that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors. The patent, number 7,553,876, entitled "Polycationic Compounds and Uses Thereof," relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis. Angiogenesis is a process involving the growth of new blood vessels. The abnormal growth of new blood vessels is associated with many diseases, including age-related macular degeneration (AMD), the most common form of blindness in the elderly, cancers, and inflammation. Inhibiting abnormal angiogenesis may be useful therapy for these conditions. Lucentis® and Macugen® are two products currently approved for treatment of AMD. PolyMedix"s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). "This is an exciting accomplishment for PolyMedix. This patent represents the first allowance from our applications relating to angiogenesis inhibition, and another compelling example of the efficiency and capabilities of our drug discovery approach," commented Nicholas Landekic, President and Chief Executive Officer. PolyMedix, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009